市場調査レポート

商品コード

1593740

鎮痛剤の世界市場の評価：薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Analgesics Market Assessment, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年11月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 246 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 646,065円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 818,349円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,177,274円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の鎮痛剤の市場規模は、2023年の374億2,000万米ドルから2031年に603億7,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで6.16%の成長が見込まれます。鎮痛剤に対する需要の高まりは、老年人口の急速な増加、慢性疾患や障害の罹患率の増加、さまざまな症状の治療に向けた手術による介入に対する需要の高まりによるものと考えられます。患者の心身の健康を確保し、日常生活への復帰を容易にするために、子宮摘出術を含むさまざまな外科手術に対する要求が高まっていることは、手術関連の疼痛を管理する世界の鎮痛剤市場の需要を増大させている大きな要因の1つです。腹式子宮摘出術は米国でもっとも一般的に行われている婦人科手術です。

さらに、慢性疾患や障害の有病率の上昇も、世界の鎮痛剤市場の成長を後押ししています。多くの場合、生涯続く慢性疾患の患者は、適切な治療が頻繁に必要とされるため、痛みを効果的に管理する非侵襲的な代替手段を好みます。非侵襲的な鎮痛法は患者に使いやすさをもたらすため、患者が頻繁に鎮痛を必要とするようなケースでは不可欠です。一方、老年人口の増加も鎮痛剤市場の需要を押し上げています。老年人口は協調の欠如のために疾患になったり怪我をしたりしやすいからです。

さらに、世界中の政府や規制機関は、手術や慢性疾患の疼痛管理に従来使用されてきたオピオイド系鎮痛剤の代替となる非オピオイド系鎮痛剤の開発を後押しする動きを強めており、非オピオイド系鎮痛剤の利用可能性を高めることで市場の拡大にプラスの影響を与えています。2022年2月、米国食品医薬品局（FDA）は、オピオイドへの曝露を減らし、急性疼痛を管理するための非中毒性のオピオイド代替薬の開発を促進する新たな措置を発表しました。米国保健社会福祉省のオピオイド危機に対抗するFive-Point Strategyの一環として、FDAはあらゆる面からこのエピデミックに取り組んでおり、適切な処方を奨励し、改良型疼痛緩和ソリューションの開発を促進する措置を講じることにより、新たな中毒を予防し、オピオイドへの曝露を減少させることに大いに注力しています。

当レポートでは、世界の鎮痛剤市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- 薬剤クラス別
- 投与経路別
- 用途別
- 流通チャネル別
- 地域別
- 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
市場マップ分析（2023年）
- 薬剤クラス別
- 投与経路別
- 用途別
- 流通チャネル別
- 地域別

第5章北米の鎮痛剤市場の見通し（2017年～2031年）

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- 薬剤クラス別
- 投与経路別
- 用途別
- 流通チャネル別
- シェア：国別
各国の市場の評価
- 米国の鎮痛剤市場の見通し（2017年～2031年）
- カナダ
- メキシコ

第6章欧州の鎮痛剤市場の見通し（2017年～2031年）

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
ポーランド

第7章アジア太平洋の鎮痛剤市場の見通し（2017年～2031年）

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米の鎮痛剤市場の見通し（2017年～2031年）

ブラジル
アルゼンチン

第9章中東・アフリカの鎮痛剤市場の見通し（2017年～2031年）

サウジアラビア
アラブ首長国連邦
南アフリカ
イスラエル

第10章需給分析

第11章輸入と輸出の分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章 PESTLE分析

第15章価格分析

第16章市場力学

市場促進要因
市場の課題

第17章市場の動向と発展

第18章規制枠組みとイノベーション

臨床試験
規制当局の承認

第19章特許情勢

第20章ケーススタディ

第21章競合情勢

マーケットリーダー上位5社の競合マトリクス
上位5社のSWOT分析
主要企業上位10社の情勢
- AbbVie Inc.
- Pfizer Inc.
- Endo, Inc.
- Eli Lilly and Company
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Groupe Sanofi

第22章戦略的推奨

第23章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 3. Global Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 4. Global Analgesics Market Share (%), By Application, 2017-2031F
Figure 5. Global Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 6. Global Analgesics Market Share (%), By Region, 2017-2031F
Figure 7. North America Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 8. North America Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 9. North America Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 10. North America Analgesics Market Share (%), By Application, 2017-2031F
Figure 11. North America Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 12. North America Analgesics Market Share (%), By Country, 2017-2031F
Figure 13. United States Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 14. United States Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 15. United States Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 16. United States Analgesics Market Share (%), By Application, 2017-2031F
Figure 17. United States Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 18. Canada Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 19. Canada Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 20. Canada Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 21. Canada Analgesics Market Share (%), By Application, 2017-2031F
Figure 22. Canada Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 23. Mexico Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 24. Mexico Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 25. Mexico Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 26. Mexico Analgesics Market Share (%), By Application, 2017-2031F
Figure 27. Mexico Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 28. Europe Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 29. Europe Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 30. Europe Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 31. Europe Analgesics Market Share (%), By Application, 2017-2031F
Figure 32. Europe Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Analgesics Market Share (%), By Country, 2017-2031F
Figure 34. Germany Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 35. Germany Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 36. Germany Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 37. Germany Analgesics Market Share (%), By Application, 2017-2031F
Figure 38. Germany Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. France Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 40. France Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 41. France Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 42. France Analgesics Market Share (%), By Application, 2017-2031F
Figure 43. France Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 44. Italy Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 45. Italy Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 46. Italy Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 47. Italy Analgesics Market Share (%), By Application, 2017-2031F
Figure 48. Italy Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 49. United Kingdom Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 50. United Kingdom Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 51. United Kingdom Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 52. United Kingdom Analgesics Market Share (%), By Application, 2017-2031F
Figure 53. United Kingdom Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 54. Russia Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 55. Russia Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 56. Russia Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 57. Russia Analgesics Market Share (%), By Application, 2017-2031F
Figure 58. Russia Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 59. Netherlands Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 60. Netherlands Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 61. Netherlands Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 62. Netherlands Analgesics Market Share (%), By Application, 2017-2031F
Figure 63. Netherlands Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Spain Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 65. Spain Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 66. Spain Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 67. Spain Analgesics Market Share (%), By Application, 2017-2031F
Figure 68. Spain Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 69. Turkey Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 70. Turkey Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 71. Turkey Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 72. Turkey Analgesics Market Share (%), By Application, 2017-2031F
Figure 73. Turkey Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Poland Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 75. Poland Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 76. Poland Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 77. Poland Analgesics Market Share (%), By Application, 2017-2031F
Figure 78. Poland Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 79. South America Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 80. South America Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 81. South America Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 82. South America Analgesics Market Share (%), By Application, 2017-2031F
Figure 83. South America Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 84. South America Analgesics Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 86. Brazil Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 87. Brazil Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 88. Brazil Analgesics Market Share (%), By Application, 2017-2031F
Figure 89. Brazil Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 90. Argentina Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 91. Argentina Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 92. Argentina Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Argentina Analgesics Market Share (%), By Application, 2017-2031F
Figure 94. Argentina Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Asia-Pacific Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 96. Asia-Pacific Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 97. Asia-Pacific Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 98. Asia-Pacific Analgesics Market Share (%), By Application, 2017-2031F
Figure 99. Asia-Pacific Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. Asia-Pacific Analgesics Market Share (%), By Country, 2017-2031F
Figure 101. India Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 102. India Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 103. India Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 104. India Analgesics Market Share (%), By Application, 2017-2031F
Figure 105. India Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 106. China Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 107. China Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 108. China Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 109. China Analgesics Market Share (%), By Application, 2017-2031F
Figure 110. China Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 111. Japan Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 112. Japan Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 113. Japan Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 114. Japan Analgesics Market Share (%), By Application, 2017-2031F
Figure 115. Japan Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. Australia Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 117. Australia Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 118. Australia Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 119. Australia Analgesics Market Share (%), By Application, 2017-2031F
Figure 120. Australia Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 121. Vietnam Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 122. Vietnam Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 123. Vietnam Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 124. Vietnam Analgesics Market Share (%), By Application, 2017-2031F
Figure 125. Vietnam Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. South Korea Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 127. South Korea Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 128. South Korea Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 129. South Korea Analgesics Market Share (%), By Application, 2017-2031F
Figure 130. South Korea Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Indonesia Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 132. Indonesia Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 133. Indonesia Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 134. Indonesia Analgesics Market Share (%), By Application, 2017-2031F
Figure 135. Indonesia Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 136. Philippines Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 137. Philippines Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 138. Philippines Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 139. Philippines Analgesics Market Share (%), By Application, 2017-2031F
Figure 140. Philippines Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 141. Middle East & Africa Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 142. Middle East & Africa Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 143. Middle East & Africa Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 144. Middle East & Africa Analgesics Market Share (%), By Application, 2017-2031F
Figure 145. Middle East & Africa Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. Middle East & Africa Analgesics Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 148. Saudi Arabia Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 149. Saudi Arabia Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 150. Saudi Arabia Analgesics Market Share (%), By Application, 2017-2031F
Figure 151. Saudi Arabia Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 152. UAE Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 153. UAE Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 154. UAE Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 155. UAE Analgesics Market Share (%), By Application, 2017-2031F
Figure 156. UAE Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 157. South Africa Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 158. South Africa Analgesics Market Share (%), By Drug Class, 2017-2031F
Figure 159. South Africa Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 160. South Africa Analgesics Market Share (%), By Application, 2017-2031F
Figure 161. South Africa Analgesics Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12251

Global analgesics market is projected to witness a CAGR of 6.16% during the forecast period 2024-2031, growing from USD 37.42 billion in 2023 to USD 60.37 billion in 2031. The rising requirement for analgesics can be attributed to the rapid growth of the geriatric population, increasing incidences of chronic diseases and disorders, and the growing requirement for surgical intervention for treating various conditions. The rising requirement for different surgical procedures, including hysterectomies, to ensure the health and well-being of patients and aid them in returning to their daily activities with ease is one of the major factors augmenting the global analgesics market demand to manage surgery-related pain. Abdominal hysterectomy is the most common gynecological surgery performed in the United States.

Furthermore, the rising prevalence of chronic diseases and disorders is also boosting the global analgesics market growth. Patients suffering from chronic conditions that often are lifelong prefer non-invasive alternatives to effectively manage their pain due to the frequent requirement of appropriate therapies. Non-invasive pain relief methods provide ease of use to the patients, which is vital in cases where the patients might require frequent pain relief. Meanwhile, the growth of the geriatric population is also propelling the demand for the analgesics market, as the older population is more prone to falling ill and getting injured due to lack of coordination.

Additionally, the government and regulatory bodies across the globe are increasingly working on boosting the development of non-opioid alternatives for opioid-based analgesics that have been traditionally used for managing pain in cases of surgeries and chronic health conditions, positively influencing the market's expansion by ensuring the increased availability of non-opioid analgesics. In February 2022, the U.S. Food and Drug Administration (FDA) unveiled new steps to foster the development of alternatives to opioids that are non-addictive for decreasing exposure to opioids and managing acute pain. As part of the United States Department of Health and Human Services' Five-Point Strategy to combat the opioid crisis, the FDA is addressing the epidemic on all fronts and significantly focusing on preventing new addictions and decreasing exposure to opioids by taking measures to encourage appropriate prescribing and promoting the development of improved pain relief solutions.

Increasing Cases of Chronic Conditions Boost Market Demand

The rising cases of chronic diseases and injuries are one of the major factors propelling the requirement for different types of analgesics. As per the estimates of the Christopher & Dana Reeve Foundation, approximately 18,000 new cases of spinal cord injury are reported in the United States every year. This increase in cases of spinal cord injuries is augmenting the requirement for various pain management solutions, including analgesics. Neuropathic or nerve pain is most common in cases of spinal cord injuries and is often described as a tight, burning, aching, or squeezing pain. Additionally, patients with spinal cord injuries also often suffer from musculoskeletal pain in the area above the injury, thus increasing the reliance on analgesics for pain relief. Moreover, the rising cases of cancer, among other chronic diseases, are also increasing the requirement for analgesics. Individuals with cancer experience pain due to the cancer treatment, the cancer itself, or a combination of both. Pain can arise from varying sources, and the pain relief offered depends upon the severity and type of pain, along with the general level of fitness and health of the patient. In cases of severe cancer pain, fast-acting opioids, fentanyl, or morphine are commonly used.

Rising Requirement for Surgical Procedures Supports Market Expansion

The growing requirement for surgical procedures for treating and managing various health conditions is boosting the requirement for different types of analgesics to manage postoperative pain. The estimated increase in the requirement for surgical procedures can be attributed to increasing incidences of road traffic accidents, metabolic diseases, and rising cases of cardiovascular disorders. According to the estimates of the U.S. Centers for Disease Control and Prevention, in 2022, approximately 702,880 people died from heart disease in the United States. This increase and the severe nature of the condition are augmenting the requirement for surgical interventions and propelling the reliance on analgesics for managing surgical pain. Postoperative pain control aids patients in transitioning smoothly back to their normal functions and is essential for reducing the various negative consequences associated with acute postsurgical pain, thus increasing the requirement for opioid analgesics and providing lucrative growth opportunities to the market.

Traditionally, opioid analgesic therapy has been used for treating acute postoperative pain. However, concerns about the misuse of opioids are bolstering the demand for research activities to support the development of pain treatment strategies that focus on using a multimodal pain management approach.

Retail Pharmacies Hold Significant Market Share

The expansion of the segment can be attributed to the increasing generation of prescriptions for analgesics due to the growing prevalence of chronic conditions, increasing cases of injuries, and rapid growth of the geriatric population. Additionally, the increasing launch of over-the-counter (OTC) analgesics contributes to the significant presence of retail pharmacies.

Meanwhile, online pharmacies are expected to witness significant growth over the forecast period due to the different advantages they offer, including lucrative discounts, home delivery, and overnight shipping. Additionally, various online pharmacies are working on increasing the availability of same-day delivery services, further supporting the segment's expansion. In October 2024, Amazon Pharmacy of Amazon.com, Inc. announced their plans to double the number of cities where patients can get their medications on the same day. With the help of its advanced automation technology and vast logistics network, the company aims to solve some of the biggest issues of the pharmacy sector: affordable access to medications and lack of convenience.

North America Holds Major Market Share

The growth of the North American analgesics market can be attributed to the strong presence of key players in the region, the growth of the geriatric population, and rising cancer cases. As per the estimates of the National Cancer Institute, 2,001,140 new cases of cancer are expected to be diagnosed in the United States in 2024. This increase is propelling the requirement for analgesics in the country among cancer patients to manage the different types of cancer-related pains. Mild cancer pain is usually treated with non-opioid analgesics alone or in combination with opioids, whereas moderate to severe cancer pain is treated with strong opioids. Additionally, the growth of the market is supported by rising research and development activities that aim to create safer and more effective pain management therapies. The United States has been at the forefront of innovation, with a wide range of pharmaceutical companies in the country significantly investing in the development of novel drug delivery systems and non-opioid analgesics. Additionally, the increasing awareness about the different analgesics available for individuals living with chronic health conditions and growing efforts of the regulatory bodies in North America to increase the availability of non-opioid analgesics are also providing lucrative growth opportunities to the market.

Future Market Scenario (2024-2031F)

As per the global analgesics market analysis, the market is expected to witness significant growth over the forecast period due to rising cases of chronic diseases, increasing requirements for surgical intervention, and expansion of the geriatric population. The World Health Organization (WHO) estimates that by 2030, one in six people across the globe will be 60 or older. This growth is expected to propel the market's demand as the older population is more prone to getting sick and requires analgesics to manage pain. Furthermore, the advancements in drug delivery systems and increasing efforts to develop non-opioid pain medications are also expected to provide lucrative growth opportunities to the market.

Additionally, the demand for non-opioid analgesics is also expected to increase significantly in the coming years due to the global opioid crisis, because of which healthcare professionals are working on reducing opioid prescriptions. Regulatory bodies and governments are also supporting the efforts of pharmaceutical companies to innovate and develop new non-opioid formulations, providing lucrative growth opportunities to the market. Meanwhile, the rise in disposable incomes and growing awareness about the various options available for pain management are also expected to drive the demand for analgesics in different regions across the globe.

Key Players Landscape and Outlook

The market's key players are focusing on developing and launching new products to expand their market share. In March 2023, Pfizer Inc. announced that they had received approval from the U.S. FDA for ZAVZPRET, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray used for treating migraine. This approval marks a significant breakthrough for patients suffering from migraine who require freedom from pain to carry out their day-to-day tasks and prefer alternatives to oral medications. The introduction of the product also underscores the company's commitment to delivering novel treatment options to ensure patients with migraine receive relief. Such efforts are expected to aid the company in expanding its product portfolio and providing novel therapeutic solutions to patients worldwide.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Analgesics Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Drug Class
  - 4.2.1.1. Opioid
  - 4.2.1.2. Non-opioid
  - 4.2.1.3. Compound Medication
- 4.2.2. By Route of Administration
  - 4.2.2.1. Oral
  - 4.2.2.2. Parenteral
  - 4.2.2.3. Topical
  - 4.2.2.4. Transdermal
  - 4.2.2.5. Others
- 4.2.3. By Application
  - 4.2.3.1. Musculoskeletal Pain
  - 4.2.3.2. Dental Pain
  - 4.2.3.3. Surgical Pain
  - 4.2.3.4. Cancer Pain
  - 4.2.3.5. Neuropathic Pain
  - 4.2.3.6. Others
- 4.2.4. By Distribution Channel
  - 4.2.4.1. Hospital Pharmacies
  - 4.2.4.2. Retail Pharmacies
  - 4.2.4.3. Online Pharmacies
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Drug Class
- 4.3.2. By Route of Administration
- 4.3.3. By Application
- 4.3.4. By Distribution Channel
- 4.3.5. By Region

5. North America Analgesics Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Class
  - 5.2.1.1. Opioid
  - 5.2.1.2. Non-opioid
  - 5.2.1.3. Compound Medication
- 5.2.2. By Route of Administration
  - 5.2.2.1. Oral
  - 5.2.2.2. Parenteral
  - 5.2.2.3. Topical
  - 5.2.2.4. Transdermal
  - 5.2.2.5. Others
- 5.2.3. By Application
  - 5.2.3.1. Musculoskeletal Pain
  - 5.2.3.2. Dental Pain
  - 5.2.3.3. Surgical Pain
  - 5.2.3.4. Cancer Pain
  - 5.2.3.5. Neuropathic Pain
  - 5.2.3.6. Others
- 5.2.4. By Distribution Channel
  - 5.2.4.1. Hospital Pharmacies
  - 5.2.4.2. Retail Pharmacies
  - 5.2.4.3. Online Pharmacies
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Analgesics Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Drug Class
      - 5.3.1.2.1.1. Opioid
      - 5.3.1.2.1.2. Non-opioid
      - 5.3.1.2.1.3. Compound Medication
    - 5.3.1.2.2. By Route of Administration
      - 5.3.1.2.2.1. Oral
      - 5.3.1.2.2.2. Parenteral
      - 5.3.1.2.2.3. Topical
      - 5.3.1.2.2.4. Transdermal
      - 5.3.1.2.2.5. Others
    - 5.3.1.2.3. By Application
      - 5.3.1.2.3.1. Musculoskeletal Pain
      - 5.3.1.2.3.2. Dental Pain
      - 5.3.1.2.3.3. Surgical Pain
      - 5.3.1.2.3.4. Cancer Pain
      - 5.3.1.2.3.5. Neuropathic Pain
      - 5.3.1.2.3.6. Others
    - 5.3.1.2.4. By Distribution Channel
      - 5.3.1.2.4.1. Hospital Pharmacies
      - 5.3.1.2.4.2. Retail Pharmacies
      - 5.3.1.2.4.3. Online Pharmacies
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Analgesics Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Analgesics Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Analgesics Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Analgesics Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

18.1. Clinical Trials
18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. AbbVie Inc.
  - 21.3.1.1. Company Details
  - 21.3.1.2. Key Management Personnel
  - 21.3.1.3. Products and Services
  - 21.3.1.4. Financials (As Reported)
  - 21.3.1.5. Key Market Focus and Geographical Presence
  - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 21.3.2. Pfizer Inc.
- 21.3.3. Endo, Inc.
- 21.3.4. Eli Lilly and Company
- 21.3.5. Bayer AG
- 21.3.6. Abbott Laboratories
- 21.3.7. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
- 21.3.8. GlaxoSmithKline plc
- 21.3.9. Teva Pharmaceutical Industries Ltd.
- 21.3.10. Groupe Sanofi

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

鎮痛剤の世界市場の評価：薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Analgesics Market Assessment, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の鎮痛剤市場の見通し（2017年～2031年）

第5章 北米の鎮痛剤市場の見通し（2017年～2031年）

第6章 欧州の鎮痛剤市場の見通し（2017年～2031年）

第7章 アジア太平洋の鎮痛剤市場の見通し（2017年～2031年）

第8章 南米の鎮痛剤市場の見通し（2017年～2031年）

第9章 中東・アフリカの鎮痛剤市場の見通し（2017年～2031年）

第10章 需給分析

第11章 輸入と輸出の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析